Microglia are the brain’s resident immune cells. They prune synapses, clear debris and respond to stress, and in animal studies chronic stress changes them in ways that drive anxiety- and depression-like behavior. Brain-imaging studies find, on average, a modest rise in a microglial marker in people with depression. The few imaging studies in PTSD have not found that rise, and no approved treatment targets microglia.
That is the short answer. The longer one is more useful, because microglia research belongs to a wider body of evidence that chronic threat is registered by the body’s immune machinery and not only by the mind. My argument here is that microglia research strengthens the case for treating depression, trauma and addiction as whole-organism states shaped by stress, sleep and personal history. The same research also shows that the immune story is partial, inconsistent across diagnoses, and not yet a treatment. The first half is why this science belongs in a therapist’s thinking; the second is why to be wary of anyone selling a cure built on it.
What microglia are, and why they changed the picture
Microglia were named in 1919 by the Spanish neuroanatomist Pío del Río-Hortega, a product of Santiago Ramón y Cajal’s school. In four papers published that year he described their shape and distribution, their ability to swallow debris, and their change into a rounded, amoeba-like form in diseased tissue. He also argued that they arose from the mesoderm rather than from the neural tissue around them.1 About ninety years later, a fate-mapping study in mice showed that adult microglia descend from primitive myeloid progenitors that appear before embryonic day 8. They are a lineage distinct from the blood-borne macrophages found elsewhere in the body.2 Put plainly, microglia are immune cells that move into the brain very early and then maintain their own population there for life.
For most of the twentieth century they were treated as a standby crew that woke up only for infection, stroke or injury. Two lines of work changed that. In 2005, Axel Nimmerjahn and colleagues watched microglia in the living mouse cortex with two-photon imaging. The supposedly resting cells were constantly extending and retracting their processes to survey their surroundings, and when the blood-brain barrier was breached they switched immediately from patrolling to shielding the injured site.3 Then work from Beth Stevens’s laboratory showed that microglia engulf synapses during normal development. The process depends on neural activity and on complement signaling, the same tagging system the immune system uses to mark microbes for removal, and disrupting it left lasting deficits in how circuits were wired.4 The cells that defend the brain also sculpt it.
That double role is why microglia matter for psychiatry. If the cells that prune connections also respond to stress hormones, inflammatory signals and even the bacteria in the gut, then experience and immunity can both reach the physical wiring of the brain. Mice raised germ-free, without gut microbes, have immature and poorly responsive microglia, and the cells partly recover when a complex microbiota is restored.5 Genetics points the same way: variants of the complement gene C4 are associated with schizophrenia in proportion to how much C4A they lead the brain to make, and in mice C4 drives synapse elimination during development.6 We cover that illness in our guide to schizophrenia myths and facts. A 2017 review by Michael Salter and Beth Stevens summed up the shift in its title: microglia have emerged as central players in brain disease.7
The journalist Donna Jackson Nakazawa brought this field to general readers in The Angel and the Assassin (2020).8 Her earlier book, Childhood Disrupted (2015), grew out of her own medical history. She writes that she was paralyzed twice in her forties by Guillain-Barré syndrome and spent more than a dozen years managing autoimmune illness, which led her to the research linking childhood adversity to adult disease.9 Her books are a reasonable place to start, but the evidence is in the studies below, and it is less tidy than the popular version.
Microglia and depression: a real signal, and a modest one
The link between inflammation and depressive symptoms predates microglia research and rests on solid ground. When the immune system fights an infection, cytokines signal the brain to produce sickness behavior: fatigue, withdrawal, poor appetite, loss of pleasure. Robert Dantzer and colleagues argued in 2008 that when this signaling continues unchecked, as in systemic infection, cancer or autoimmune disease, it can tip vulnerable people into clinical depression, which may help explain why depression is so common in physical illness.10 The cleanest human demonstration came from cancer care. Interferon alfa, an immune-stimulating drug given to people with melanoma, caused depression often enough that an Emory team tested starting an antidepressant two weeks beforehand. In that 40-patient trial, over the first 12 weeks of interferon, 45 percent of the placebo group developed symptoms consistent with major depression, against 11 percent of the paroxetine group.11
Inflammation is not present in every depressed person, though. A 2019 meta-analysis of 37 studies covering more than 13,500 depressed patients found low-grade inflammation, defined as C-reactive protein (CRP) above 3 mg/L, in about 27 percent, and mildly raised CRP, above 1 mg/L, in about 58 percent.12 Inflammation looks relevant to a large minority of people with depression, not to depression as such. Andrew Miller and Charles Raison argue that inflammatory alarm responses once helped humans survive pathogens and predators, and that under modern conditions the same immune-brain crosstalk may drive depression and blunt the response to antidepressants.13
Blood markers measure the body, not the brain. To look inside, researchers use PET scans with tracers that bind the 18 kDa translocator protein (TSPO), which microglia express. In a 2015 Toronto study of 20 people in a major depressive episode, TSPO binding was 26 to 33 percent higher than in healthy controls across the prefrontal cortex, anterior cingulate and insula, and higher anterior cingulate binding went with more severe depression.14 A 2022 meta-analysis pooled eight PET studies, 238 patients and 164 controls, and found an average increase of roughly 18 percent, with the largest effects in the anterior cingulate and hippocampus.15 A 2019 review found raised cytokines in the cerebrospinal fluid of people with depression but split post-mortem results: two studies found increased microglial markers and four found no change.16
Three caveats keep this from being the “brain on fire” story it is sometimes sold as. First, not every study finds the signal. A Yale study of ten people with mild to moderate depression found no increase, and seven of the ten actually had lower binding than their genotype-matched controls.17 Second, the 2022 meta-analysis found no relationship between TSPO levels and how severe the depression was.15 Third, TSPO is an imperfect marker. It is carried by other immune cells, such as macrophages, as well as by microglia. Laboratory work on human cells found that, unlike in rodents, pro-inflammatory activation of human microglia does not raise TSPO expression, which suggests the scans may track how many of these cells are present rather than how inflamed they are.18 An 18 percent difference in a density marker is a real finding. It is not a picture of a burning brain.
The animal work adds causation, and a surprise. In Raz Yirmiya’s laboratory in Jerusalem, mice under five weeks of chronic unpredictable stress first showed a burst of microglial proliferation and activation. By the end, some hippocampal microglia had died, their numbers had fallen, and the remaining cells looked shrunken and dystrophic. Blocking the early activation prevented the later depressive-like behavior, and in mice already in that state, treatments that stimulated microglia partly or fully reversed it.19 In Ronald Duman’s laboratory, Eric Wohleb and colleagues found that chronic stress raised prefrontal levels of a neuronal signal, CSF1, while microglia engulfed more pieces of neurons and dendritic spines were lost. Knocking down neuronal CSF1 prevented the behavioral effects, and CSF1 messenger RNA was also elevated in post-mortem prefrontal tissue from people with depression.20 The lesson is that “too much inflammation” is too simple. Microglia can be overactive, exhausted or misdirected, and which state matters may depend on how long the stress has lasted.
One small study from Budapest deserves mention because it is easy to overread. Li, Sagar and Kéri scanned newly diagnosed patients before and after cognitive-behavioral therapy or supportive psychotherapy. TSPO binding fell during CBT, though not during supportive therapy, and the drop tracked symptom improvement.21 It is an interesting result, but a single one, with 20 patients per group, from one laboratory. Read it as a lead, not as proof that therapy works by calming microglia.
Trauma, stress and “primed” microglia
The idea in this literature that rings truest clinically is priming. Matthew Frank, Linda Watkins, Steven Maier and colleagues have reviewed rodent evidence, much of it their own, that a prior stressor, or exposure to stress hormones, sensitizes the brain’s immune environment: a later immune challenge then produces an exaggerated inflammatory response in the brain and exaggerated sickness behavior. They propose that this stress-induced sensitization is one route into psychiatric illness.22 Stress hormones are usually thought of as anti-inflammatory. The priming work shows that over time, in the brain, they can set the stage for the opposite.
Repeated social defeat, in which a mouse is repeatedly confronted and dominated by an aggressive one, is a closer model of interpersonal threat. In work by Eric Wohleb, John Sheridan and colleagues, it produced anxiety-like behavior, inflammatory changes in microglia of the amygdala, prefrontal cortex and hippocampus, and an influx of inflammatory macrophages into the brain. Microglia taken from defeated mice and stimulated in a dish produced much more inflammatory signaling than microglia from control mice. All of it was prevented by propranolol, which blocks the beta-adrenergic arm of the stress response.23 The animals’ immune cells were, in effect, still braced for the next attack.
In people, the evidence from blood is fairly consistent. In the Dunedin birth cohort in New Zealand, children who were maltreated were about 1.8 times as likely to have clinically relevant CRP levels at age 32, and the link held after accounting for other early risks, adult stress and health behaviors.24 A 2016 meta-analysis of 25 studies confirmed raised CRP, IL-6 and TNF-α in adults with a history of childhood trauma, though the effects were small.25 In a 2015 meta-analysis of 20 studies, people with PTSD had higher IL-6, IL-1β and interferon-γ than controls, and higher TNF-α among those not taking medication. The studies vary widely, and medication use and co-occurring depression explain much of that variation.26 Childhood adversity and trauma can leave a measurable, if modest, inflammatory trace in the body.
The brain is where the simple story breaks. When Yale researchers scanned 23 people with PTSD using a TSPO tracer, they did not find the raised microglial marker the animal work predicted. Prefrontal-limbic TSPO availability was lower than in controls, and the more severe the PTSD, the lower it was, even as higher blood CRP went with lower brain TSPO. A separate post-mortem comparison of 22 people with PTSD and 22 controls found no overall difference in gene expression, though a subgroup of women with PTSD showed lower expression of TSPO and related microglial genes.27 The authors read this as inflammation in the body paired with a blunted immune response in the brain, which challenges the view that neuroimmune activation is central to stress-related illness. The same Yale group later gave 15 people with PTSD and 15 controls a dose of bacterial endotoxin, a standard immune challenge. Brain TSPO rose less in the PTSD group, and greater anhedonia went with a more suppressed response.28 Not every study agrees. A Toronto study of 20 people with occupation-related PTSD, using a different tracer, found no significant difference from controls, with values that ran non-significantly higher.29
That should change how the primed-microglia idea gets told. Priming is well supported in rodents and plausible in some people, but the human PTSD imaging studies are few and small, none shows a brain on fire, and the Yale results point toward suppression. One possible reading, which echoes the stressed mice whose hippocampal microglia ended up depleted, is a system worn down by long activation. That is a hypothesis, not a finding.
Addiction and the neuroimmune system
The addiction research runs on the same logic. Mark Hutchinson, Linda Watkins and colleagues found that opioids activate toll-like receptor 4 (TLR4), an innate immune sensor, as well as opioid receptors. Blocking TLR4 in rats, or knocking out its signaling in mice, reduced opioid reward behavior and blunted the morphine-induced rise in dopamine in the nucleus accumbens.30 That result has been contested. A National Institute on Drug Abuse group that included two of the paper’s co-authors tested (+)-naloxone, the TLR4 blocker used in that work, and a related drug in rats across a wider range of doses. The drugs did not reduce the dopamine rise produced by heroin or cocaine, and the doses that cut drug self-administration also cut responding for food, so the effect was not specific to drug reward.31 Fulton Crews and colleagues argue that repeated cycles of alcohol and stress progressively induce innate immune signaling in the brain, and that this contributes to the loss of control, anxiety and craving of alcohol use disorder.32 The Colorado priming group links the two directly, proposing stress-primed neuroinflammation as one route to stress-induced vulnerability to drugs.33
The human data are thinner and do not line up. In a PET study of nine recently detoxified alcohol-dependent men and 20 controls, TSPO binding in the hippocampus was about 20 percent lower in the patients, not higher, and the authors found no sign of the microglial activation seen in animal models.34 The drug most tested on the neuroimmune theory is ibudilast. In a two-week trial with 52 people who were not seeking treatment, it reduced the odds of heavy drinking and dampened cue-triggered activity in the ventral striatum.35 But in a 12-week phase 2 trial of 102 treatment-seeking adults, published in 2025, ibudilast did no better than placebo on heavy drinking days or on any secondary outcome, and it did not lower blood markers of inflammation.36
None of this weakens the broader case that addiction is a condition of brain and body rather than of character, which we make in why the worst drug for you is the one that makes you feel normal. The immune contribution, though, is still a research question. The same caution applies to popular reward-system stories; our look at whether dopamine detox is pseudoscience or self-help shows how a real neurotransmitter gets turned into a slogan. If you are in recovery and want ongoing support, our page on therapy after drug and alcohol rehab describes that work.
Why there is still no microglia treatment
Researchers have tried to treat inflammation in depression, and the results show where the field stands. Infliximab, an antibody that blocks the inflammatory cytokine TNF, had no overall effect on treatment-resistant depression in a 60-patient trial led by Charles Raison and Andrew Miller. Patients whose baseline CRP was above 5 mg/L tended to do better on the drug, while those with lower CRP tended to do better on placebo.37 That trial tested inflammation broadly, not microglia specifically. Minocycline, an antibiotic that inhibits microglial activation in animal studies, is the closest thing to a microglia drug in psychiatric trials. In a German multicenter trial with 168 people in the analysis, adding minocycline to antidepressant treatment for six weeks did no better than placebo.38 A smaller London trial of 39 patients, which enrolled only those with CRP of at least 1 mg/L, found benefit only in the subgroup at 3 mg/L or above.39
The pattern holds across these trials: no general effect, and possible benefit in a subgroup with measurable inflammation. That is a real research direction, sometimes called inflammatory depression, and it is why there is nothing yet to buy. No medication is approved for depression, PTSD or addiction on the grounds that it acts on microglia. If you have depression alongside a known inflammatory or autoimmune condition, raise it with your physician or prescriber, who can decide whether tests such as CRP make sense for you. Do not start, stop or change any medication or supplement because of this research without that conversation. The same caution applies to supplements marketed as anti-inflammatory brain support; our review of NAD+ for mental health shows how far marketing can run ahead of the trials.
McGilchrist and the hemispheres: a lens, not a finding
This post’s title also names Iain McGilchrist, a psychiatrist and former Fellow of All Souls College, Oxford. His book The Master and His Emissary (2009) argues that the two cerebral hemispheres attend to the world in different ways, and that the balance between them has shaped Western culture as well as individual minds.40 His own peer-reviewed summary is more careful than the popular version. Across reptiles, birds and mammals, he writes, one hemisphere tends to apply narrow, precisely focused attention suited to grasping food or prey, and the other a broad, open attention suited to watching for predators and reading others of the same species. He locates the difference in modes of attention within any task, not in separate functions such as logic versus emotion.41
The popular notion of “left-brained” and “right-brained” people is not supported. An analysis of resting-state scans from 1,011 people found that lateralization is a property of local networks, not a whole-brain trait that sorts people into types.42 McGilchrist’s attention-based framing rejects that pop version too. And there is no research connecting microglia to his hemispheric thesis. An earlier version of this page joined the two; that was interpretation, not finding. Much of the classic experimental evidence for hemispheric specialization comes from split-brain research, which we cover in our piece on Michael Gazzaniga.
Why keep McGilchrist in the piece at all? Because his framework names a habit of mind that the microglia story invites. The narrow, grasping move takes a complex, context-bound illness and looks for the one part to fix: yesterday a neurotransmitter, today an immune cell. The broader move holds the parts in relation. A cell type that responds to stress hormones, gut bacteria, sleep, infection and personal history is a reason to look at the whole life around a symptom, not to trade one chemical target for another. It sits comfortably beside Daniel Siegel’s emphasis on integration, which we discuss in our profile of Daniel Siegel.
What this looks like in therapy
We do not treat microglia, and no psychotherapy has been shown to work by changing them. What this research changes is how a clinician understands the person in the room.
Symptoms that look like sickness get taken seriously as possible sickness. Fatigue, poor appetite, withdrawal and loss of pleasure are core features of sickness behavior.10 When those dominate a depression, especially alongside autoimmune disease, chronic infection or a recent serious illness, a good therapist asks whether the person’s physician knows and encourages a medical evaluation, rather than assuming the cause is purely psychological.
Sleep is part of the work, not a side issue. A meta-analysis of 72 studies with more than 50,000 participants linked sleep disturbance to higher CRP and IL-6. Notably, brief experimental sleep deprivation did not raise those markers.43 In mice, about five days of chronic sleep restriction, but not six to eight hours of acute sleep deprivation, produced signs of microglial activation and increased microglial engulfment of synapses.44 In both cases it is the chronic pattern that matters. For trauma survivors, poor sleep is often bound up with nighttime hypervigilance, and working on it directly is part of trauma treatment.
Trauma work is understood as work with a whole-body state. The animal priming studies and the human inflammation data both describe a threat system that stays switched on after the threat is over. That is the territory of trauma-focused and somatic therapies, which aim to help the nervous system register that the danger has passed. There is evidence that psychosocial treatment reaches the immune system, at least as measured in blood. A 2020 meta-analysis of 56 randomized trials and 4,060 participants found that psychosocial interventions, most reliably CBT and combined approaches, were associated with an 18 percent decrease in markers of harmful immune activity such as pro-inflammatory cytokines, with effects lasting at least six months.45 That is blood work, not brain imaging.
The vagus nerve has a real immune role, and an overstated one. Kevin Tracey’s work on the “inflammatory reflex” showed in animals that vagus nerve signaling can dampen cytokine production.46 In a small 2016 study with no control group, an implanted vagus nerve stimulator reduced TNF production and improved disease scores in people with rheumatoid arthritis. Several authors were employees of or held equity in SetPoint Medical, which also funded the clinical work.47 That is an implanted device changing cytokine production in the blood. It is not evidence that breathing exercises reprogram microglia. We sort the devices from the claims in our clinician’s guide to neuro-tech and vagal nerve stimulators.
Hope is kept honest. People who have read about inflammation sometimes arrive believing their depression is “just inflammation” and that the answer is a pill or a diet. Others arrive relieved that their suffering has a biology at all. The honest middle is that biology and history are not competing explanations. Stress changes immune cells, immune cells change brain circuits, and changed circuits shape how a person meets the next stress. Therapy works on the parts of that loop a person can reach: what they carry, how their body braces, how they sleep, and who they are with.
If depression has settled in and the usual explanations have not helped, it may be worth working with someone who takes both the body and the history seriously. Our page on depression treatment in Hoover describes how we approach it, and you can reach us through our contact page. If you are in crisis, call or text 988 to reach the 988 Suicide and Crisis Lifeline.
References
- Sierra, A., de Castro, F., del Río-Hortega, J., Rafael Iglesias-Rozas, J., Garrosa, M., & Kettenmann, H. (2016). The “Big-Bang” for modern glial biology: Translation and comments on Pío del Río-Hortega 1919 series of papers on microglia. Glia, 64(11), 1801–1840. https://doi.org/10.1002/glia.23046
- Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., Samokhvalov, I. M., & Merad, M. (2010). Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science, 330(6005), 841–845. https://doi.org/10.1126/science.1194637
- Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science, 308(5726), 1314–1318. https://doi.org/10.1126/science.1110647
- Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012). Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron, 74(4), 691–705. https://doi.org/10.1016/j.neuron.2012.03.026
- Erny, D., Hrabě de Angelis, A. L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., Keren-Shaul, H., Mahlakoiv, T., Jakobshagen, K., Buch, T., Schwierzeck, V., Utermöhlen, O., Chun, E., Garrett, W. S., McCoy, K. D., Diefenbach, A., Staeheli, P., Stecher, B., Amit, I., & Prinz, M. (2015). Host microbiota constantly control maturation and function of microglia in the CNS. Nature Neuroscience, 18(7), 965–977. https://doi.org/10.1038/nn.4030
- Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., Genovese, G., Rose, S. A., Handsaker, R. E., Schizophrenia Working Group of the Psychiatric Genomics Consortium, Daly, M. J., Carroll, M. C., Stevens, B., & McCarroll, S. A. (2016). Schizophrenia risk from complex variation of complement component 4. Nature, 530(7589), 177–183. https://doi.org/10.1038/nature16549
- Salter, M. W., & Stevens, B. (2017). Microglia emerge as central players in brain disease. Nature Medicine, 23(9), 1018–1027. https://doi.org/10.1038/nm.4397
- Nakazawa, D. J. (2020). The angel and the assassin: The tiny brain cell that changed the course of medicine. Ballantine Books.
- Nakazawa, D. J. (2015). Childhood disrupted: How your biography becomes your biology, and how you can heal. Atria Books.
- Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008). From inflammation to sickness and depression: When the immune system subjugates the brain. Nature Reviews Neuroscience, 9(1), 46–56. https://doi.org/10.1038/nrn2297
- Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001). Paroxetine for the prevention of depression induced by high-dose interferon alfa. New England Journal of Medicine, 344(13), 961–966. https://doi.org/10.1056/NEJM200103293441303
- Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B., & Khandaker, G. M. (2019). Prevalence of low-grade inflammation in depression: A systematic review and meta-analysis of CRP levels. Psychological Medicine, 49(12), 1958–1970. https://doi.org/10.1017/S0033291719001454
- Miller, A. H., & Raison, C. L. (2016). The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nature Reviews Immunology, 16(1), 22–34. https://doi.org/10.1038/nri.2015.5
- Setiawan, E., Wilson, A. A., Mizrahi, R., Rusjan, P. M., Miler, L., Rajkowska, G., Suridjan, I., Kennedy, J. L., Rekkas, P. V., Houle, S., & Meyer, J. H. (2015). Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry, 72(3), 268–275. https://doi.org/10.1001/jamapsychiatry.2014.2427
- Eggerstorfer, B., Kim, J.-H., Cumming, P., Lanzenberger, R., & Gryglewski, G. (2022). Meta-analysis of molecular imaging of translocator protein in major depression. Frontiers in Molecular Neuroscience, 15, 981442. https://doi.org/10.3389/fnmol.2022.981442
- Enache, D., Pariante, C. M., & Mondelli, V. (2019). Markers of central inflammation in major depressive disorder: A systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain, Behavior, and Immunity, 81, 24–40. https://doi.org/10.1016/j.bbi.2019.06.015
- Hannestad, J., DellaGioia, N., Gallezot, J.-D., Lim, K., Nabulsi, N., Esterlis, I., Pittman, B., Lee, J.-Y., O’Connor, K. C., Pelletier, D., & Carson, R. E. (2013). The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A 11C-PBR28 PET study. Brain, Behavior, and Immunity, 33, 131–138. https://doi.org/10.1016/j.bbi.2013.06.010
- Owen, D. R., Narayan, N., Wells, L., Healy, L., Smyth, E., Rabiner, E. A., Galloway, D., Williams, J. B., Lehr, J., Mandhair, H., Peferoen, L. A., Taylor, P. C., Amor, S., Antel, J. P., Matthews, P. M., & Moore, C. S. (2017). Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. Journal of Cerebral Blood Flow & Metabolism, 37(8), 2679–2690. https://doi.org/10.1177/0271678X17710182
- Kreisel, T., Frank, M. G., Licht, T., Reshef, R., Ben-Menachem-Zidon, O., Baratta, M. V., Maier, S. F., & Yirmiya, R. (2014). Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Molecular Psychiatry, 19(6), 699–709. https://doi.org/10.1038/mp.2013.155
- Wohleb, E. S., Terwilliger, R., Duman, C. H., & Duman, R. S. (2018). Stress-induced neuronal colony stimulating factor 1 provokes microglia-mediated neuronal remodeling and depressive-like behavior. Biological Psychiatry, 83(1), 38–49. https://doi.org/10.1016/j.biopsych.2017.05.026
- Li, H., Sagar, A. P., & Kéri, S. (2018). Translocator protein (18 kDa TSPO) binding, a marker of microglia, is reduced in major depression during cognitive-behavioral therapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 83, 1–7. https://doi.org/10.1016/j.pnpbp.2017.12.011
- Frank, M. G., Weber, M. D., Watkins, L. R., & Maier, S. F. (2016). Stress-induced neuroinflammatory priming: A liability factor in the etiology of psychiatric disorders. Neurobiology of Stress, 4, 62–70. https://doi.org/10.1016/j.ynstr.2015.12.004
- Wohleb, E. S., Hanke, M. L., Corona, A. W., Powell, N. D., Stiner, L. M., Bailey, M. T., Nelson, R. J., Godbout, J. P., & Sheridan, J. F. (2011). β-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. The Journal of Neuroscience, 31(17), 6277–6288. https://doi.org/10.1523/JNEUROSCI.0450-11.2011
- Danese, A., Pariante, C. M., Caspi, A., Taylor, A., & Poulton, R. (2007). Childhood maltreatment predicts adult inflammation in a life-course study. Proceedings of the National Academy of Sciences, 104(4), 1319–1324. https://doi.org/10.1073/pnas.0610362104
- Baumeister, D., Akhtar, R., Ciufolini, S., Pariante, C. M., & Mondelli, V. (2016). Childhood trauma and adulthood inflammation: A meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α. Molecular Psychiatry, 21(5), 642–649. https://doi.org/10.1038/mp.2015.67
- Passos, I. C., Vasconcelos-Moreno, M. P., Costa, L. G., Kunz, M., Brietzke, E., Quevedo, J., Salum, G., Magalhães, P. V., Kapczinski, F., & Kauer-Sant’Anna, M. (2015). Inflammatory markers in post-traumatic stress disorder: A systematic review, meta-analysis, and meta-regression. The Lancet Psychiatry, 2(11), 1002–1012. https://doi.org/10.1016/S2215-0366(15)00309-0
- Bhatt, S., Hillmer, A. T., Girgenti, M. J., Rusowicz, A., Kapinos, M., Nabulsi, N., Huang, Y., Matuskey, D., Angarita, G. A., Esterlis, I., Davis, M. T., Southwick, S. M., Friedman, M. J., Traumatic Stress Brain Study Group, Duman, R. S., Carson, R. E., Krystal, J. H., Pietrzak, R. H., & Cosgrove, K. P. (2020). PTSD is associated with neuroimmune suppression: Evidence from PET imaging and postmortem transcriptomic studies. Nature Communications, 11(1), 2360. https://doi.org/10.1038/s41467-020-15930-5
- Bonomi, R., Hillmer, A. T., Woodcock, E., Bhatt, S., Rusowicz, A., Angarita, G. A., Carson, R. E., Davis, M. T., Esterlis, I., Nabulsi, N., Huang, Y., Krystal, J. H., Pietrzak, R. H., & Cosgrove, K. P. (2024). Microglia-mediated neuroimmune suppression in PTSD is associated with anhedonia. Proceedings of the National Academy of Sciences, 121(35), e2406005121. https://doi.org/10.1073/pnas.2406005121
- Watling, S. E., Gill, T., Gaudette, E. V., Richardson, J. D., McCluskey, T., Tong, J., Meyer, J. H., Warsh, J., Jetly, R., Hutchison, M. G., Rhind, S. G., Houle, S., Kish, S. J., & Boileau, I. (2023). Investigating TSPO levels in occupation-related posttraumatic stress disorder. Scientific Reports, 13(1), 4970. https://doi.org/10.1038/s41598-023-31327-y
- Hutchinson, M. R., Northcutt, A. L., Hiranita, T., Wang, X., Lewis, S. S., Thomas, J., van Steeg, K., Kopajtic, T. A., Loram, L. C., Sfregola, C., Galer, E., Miles, N. E., Bland, S. T., Amat, J., Rozeske, R. R., Maslanik, T., Chapman, T. R., Strand, K. A., Fleshner, M., . . . Watkins, L. R. (2012). Opioid activation of toll-like receptor 4 contributes to drug reinforcement. The Journal of Neuroscience, 32(33), 11187–11200. https://doi.org/10.1523/JNEUROSCI.0684-12.2012
- Tanda, G., Mereu, M., Hiranita, T., Quarterman, J. C., Coggiano, M., & Katz, J. L. (2016). Lack of specific involvement of (+)-naloxone and (+)-naltrexone on the reinforcing and neurochemical effects of cocaine and opioids. Neuropsychopharmacology, 41(11), 2772–2781. https://doi.org/10.1038/npp.2016.91
- Crews, F. T., Lawrimore, C. J., Walter, T. J., & Coleman, L. G., Jr. (2017). The role of neuroimmune signaling in alcoholism. Neuropharmacology, 122, 56–73. https://doi.org/10.1016/j.neuropharm.2017.01.031
- Frank, M. G., Watkins, L. R., & Maier, S. F. (2011). Stress- and glucocorticoid-induced priming of neuroinflammatory responses: Potential mechanisms of stress-induced vulnerability to drugs of abuse. Brain, Behavior, and Immunity, 25(Suppl. 1), S21–S28. https://doi.org/10.1016/j.bbi.2011.01.005
- Kalk, N. J., Guo, Q., Owen, D., Cherian, R., Erritzoe, D., Gilmour, A., Ribeiro, A. S., McGonigle, J., Waldman, A., Matthews, P., Cavanagh, J., McInnes, I., Dar, K., Gunn, R., Rabiner, E. A., & Lingford-Hughes, A. R. (2017). Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: A 11C-PBR28 PET study. Translational Psychiatry, 7(1), e996. https://doi.org/10.1038/tp.2016.264
- Grodin, E. N., Bujarski, S., Towns, B., Burnette, E., Nieto, S., Lim, A., Lin, J., Miotto, K., Gillis, A., Irwin, M. R., Evans, C., & Ray, L. A. (2021). Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: A randomized trial. Translational Psychiatry, 11(1), 355. https://doi.org/10.1038/s41398-021-01478-5
- Ray, L. A., Meredith, L. R., Grodin, E. N., Belnap, M. A., Nieto, S. J., Baskerville, W. A., Donato, S., Shoptaw, S. J., Gillis, A. J., Irwin, M. R., Miotto, K., & Enders, C. K. (2025). A neuroimmune modulator for alcohol use disorder: A randomized clinical trial. JAMA Network Open, 8(4), e257523. https://doi.org/10.1001/jamanetworkopen.2025.7523
- Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry, 70(1), 31–41. https://doi.org/10.1001/2013.jamapsychiatry.4
- Hellmann-Regen, J., Clemens, V., Grözinger, M., Kornhuber, J., Reif, A., Prvulovic, D., Goya-Maldonado, R., Wiltfang, J., Gruber, O., Schüle, C., Padberg, F., Ising, M., Uhr, M., Friede, T., Huber, C., Manook, A., Baghai, T. C., Rupprecht, R., & Heuser, I. (2022). Effect of minocycline on depressive symptoms in patients with treatment-resistant depression: A randomized clinical trial. JAMA Network Open, 5(9), e2230367. https://doi.org/10.1001/jamanetworkopen.2022.30367
- Nettis, M. A., Lombardo, G., Hastings, C., Zajkowska, Z., Mariani, N., Nikkheslat, N., Worrell, C., Enache, D., McLaughlin, A., Kose, M., Sforzini, L., Bogdanova, A., Cleare, A., Young, A. H., Pariante, C. M., & Mondelli, V. (2021). Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: Results from a double-blind randomised clinical trial. Neuropsychopharmacology, 46(5), 939–948. https://doi.org/10.1038/s41386-020-00948-6
- McGilchrist, I. (2009). The master and his emissary: The divided brain and the making of the Western world. Yale University Press.
- McGilchrist, I. (2010). Reciprocal organization of the cerebral hemispheres. Dialogues in Clinical Neuroscience, 12(4), 503–515. https://doi.org/10.31887/DCNS.2010.12.4/imcgilchrist
- Nielsen, J. A., Zielinski, B. A., Ferguson, M. A., Lainhart, J. E., & Anderson, J. S. (2013). An evaluation of the left-brain vs. right-brain hypothesis with resting state functional connectivity magnetic resonance imaging. PLoS ONE, 8(8), e71275. https://doi.org/10.1371/journal.pone.0071275
- Irwin, M. R., Olmstead, R., & Carroll, J. E. (2016). Sleep disturbance, sleep duration, and inflammation: A systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biological Psychiatry, 80(1), 40–52. https://doi.org/10.1016/j.biopsych.2015.05.014
- Bellesi, M., de Vivo, L., Chini, M., Gilli, F., Tononi, G., & Cirelli, C. (2017). Sleep loss promotes astrocytic phagocytosis and microglial activation in mouse cerebral cortex. The Journal of Neuroscience, 37(21), 5263–5273. https://doi.org/10.1523/JNEUROSCI.3981-16.2017
- Shields, G. S., Spahr, C. M., & Slavich, G. M. (2020). Psychosocial interventions and immune system function: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry, 77(10), 1031–1043. https://doi.org/10.1001/jamapsychiatry.2020.0431
- Tracey, K. J. (2002). The inflammatory reflex. Nature, 420(6917), 853–859. https://doi.org/10.1038/nature01321
- Koopman, F. A., Chavan, S. S., Miljko, S., Grazio, S., Sokolovic, S., Schuurman, P. R., Mehta, A. D., Levine, Y. A., Faltys, M., Zitnik, R., Tracey, K. J., & Tak, P. P. (2016). Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proceedings of the National Academy of Sciences, 113(29), 8284–8289. https://doi.org/10.1073/pnas.1605635113



























0 Comments